Rd, guess we disagree. FDA won't give an approval with just 120 in the test group. No P 3, no approval. But if the P 2b is great, I don't think money or pps will be an issue. On the other hand, since we have not seen any real indications on what the study will entail, maybe we are both fos on this one.
"There’s no chance Leo will bother with a P3 considering the cost and the earliest it may be completed will be irrelevant."
If the Phase 2 human trials are good. It is guaranteed a quick phase 3 will follow. If a phase 3 is outstanding it will lead to broad acceptance, funding may be even a partnership. Every country in the world will want a supply.
Remember the EU paid a billion dollars for Remdesivir whose efficacy is questionable.
Covid shows no sign of letting up. An effective anti viral will be a key part of any treatment.
News 
Market Data 
Discover 
AI
